External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience ADPD 2022
Roche and Genentech at

ADPD 2022

March 15 - March 20
Barcelona, Spain / Virtual (Hybrid)
adpd.kenes
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
09:55 AM
Duration 15mins Barcelona, Spain
Patient Stratification in Alzheimer’s Disease: Opportunities and Challenges
Abdelnour C, Agosta F, Bozzali M, Fougere B, Iwata A, Nilforooshan R, Takada L, Vinuela F, Traber M
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:45 PM
Duration 15mins Barcelona, Spain
PATIENT AND CAREGIVER EXPERIENCE IN PHASE III TRIALS OF GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE: QUALITATIVE SURVEY RATIONALE AND DESIGN
Alberto Villarejo-Galende, Christine D. Pozniak, Fiona McDougall, Sheila Seleri Assunção, Wael Abouelkheir, Beverly Assman, Rozanno Gonzales, Oliver Peters, David Watson
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:00 PM
Duration 15mins Barcelona, Spain
SKYLINE study design: Efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s disease
Bullain S, Sperling R, Reiman EM, Langbaum JB, Aisen P, Johnson KA, Tariot PN, Respondek G, Garcia-Valdecasas Colell M, Wojtowicz J, Schiffman C, Bittner T, Lansdall C, Giacobino C, Delmar P, Ashford E, Baudler-Klein M, Doody RS, Ostrowitzki S
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:45 PM
Duration 15mins Barcelona, Spain
A 104-WEEK DELAYED-START ANALYSIS OF PASADENA (PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF PRASINEZUMAB IN EARLY PARKINSON'S DISEASE)
Pagano G, Zanigni S, Monnet A, Taylor KI, Hahn A, Marek K, Postuma R, Pavese N, Stocchi F, Simuni T, D'Urso G, Pross N, Lindemann M, Zago W, Kinney GG, Garren H, Tripuraneni R, Svoboda H, Fontoura P, Doody R, Kerchner GA, Bonni A, Nikolcheva T, for the PASADENA Investigators and Prasinezumab Study Group
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 15mins Barcelona, Spain
Delayed start analysis of Roche PD Mobile Application v2 in PASADENA shows persistent positive effects of prasinezumab on bradykinesia progression
Kirsten Taylor
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.